RGD Reference Report - An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model.

Authors: Uchiyama, M  Shimizu, A  Masuda, Y  Nagasaka, S  Fukuda, Y  Takahashi, H 
Citation: Uchiyama M, etal., Mol Vis. 2013 Nov 1;19:2135-50. eCollection 2013.
RGD ID: 8552904
Pubmed: PMID:24194635   (View Abstract at PubMed)
PMCID: PMC3816991   (View Article at PubMed Central)

PURPOSE: We clarified the effects of an ophthalmic solution of a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist on corneal inflammation and wound healing after alkali burn injury in rats. METHODS: After alkali exposure, either an ophthalmic solution with 0.1% pioglitazone hydrochloride (the PPARgamma group) or vehicle (the vehicle group) was topically applied to the cornea until day 14. Histological, immunohistochemical, and real-time reverse transcription polymerase chain reaction analysis were performed. RESULTS: After alkali injury, PPARgamma expression increased, with the infiltration of many inflammatory cells. The infiltration of neutrophils and macrophages started from the corneal limbus within 6 h, and developed in the corneal center by day 7, with associated neovascularization. The accumulation of alpha-smooth muscle actin-positive myofibroblasts and the deposition of type III collagen were noted on day 14. The histological changes were suppressed significantly by treatment with the ophthalmic solution of the PPARgamma agonist. In addition, the number of infiltrating M2 macrophages in the cornea was increased by PPARgamma agonist treatment. In real-time reverse transcription polymerase chain reaction analysis, the messenger ribonucleic acid expression levels of interleukin-1beta (IL-1beta), IL-6, IL-8, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, transforming growth factor beta 1, and vascular endothelial growth factor-A were decreased in the PPARgamma group compared to the vehicle group in the early periods of corneal inflammation. CONCLUSIONS: The ophthalmic solution of the PPARgamma agonist inhibited inflammation, decreased the fibrotic reaction, and prevented neovascularization in the cornea from the early phase after alkali burn injury. The ophthalmic solution of the PPARgamma agonist may provide a new treatment strategy with useful clinical applications for corneal inflammation and wound healing.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
PPARGHumanEye Burns  ISOPparg (Rattus norvegicus)protein:increased expression:cornea more ...RGD 
PpargRatEye Burns  IEP protein:increased expression:cornea more ...RGD 
PpargMouseEye Burns  ISOPparg (Rattus norvegicus)protein:increased expression:cornea more ...RGD 

Objects Annotated

Genes (Rattus norvegicus)
Pparg  (peroxisome proliferator-activated receptor gamma)

Genes (Mus musculus)
Pparg  (peroxisome proliferator activated receptor gamma)

Genes (Homo sapiens)
PPARG  (peroxisome proliferator activated receptor gamma)


Additional Information